BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oh CE, Ortiz-Brizuela E, Bastos ML, Menzies D. Comparing the Diagnostic Performance of QuantiFERON-TB Gold Plus to Other Tests of Latent Tuberculosis Infection: A Systematic Review and Meta-analysis. Clin Infect Dis 2021;73:e1116-25. [PMID: 33289038 DOI: 10.1093/cid/ciaa1822] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Campbell JR, Nsengiyumva P, Chiang LY, Jamieson F, Khadawardi H, Mah HK, Oxlade O, Rasberry H, Rea E, Romanowski K, Sabur NF, Sander B, Uppal A, Johnston JC, Schwartzman K, Brode SK. Costs of Tuberculosis at 3 Treatment Centers, Canada, 2010-2016. Emerg Infect Dis 2022;28:1814-23. [PMID: 35997366 DOI: 10.3201/eid2809.220092] [Reference Citation Analysis]
2 Mauch RM, Jensen PØ, Qvist T, Kolpen M, Moser C, Pressler T, Nolasco da Silva MT, Høiby N; Copenhagen Study Group on Mycobacterial Infections in Cystic Fibrosis. Adaptive Immune Response to Mycobacterium abscessus Complex (MABSC) in Cystic Fibrosis and the Implications of Cross-Reactivity. Front Cell Infect Microbiol 2022;12:858398. [PMID: 35548464 DOI: 10.3389/fcimb.2022.858398] [Reference Citation Analysis]
3 Carrère-kremer S, Kolia-diafouka P, Pisoni A, Bolloré K, Peries M, Godreuil S, Bourdin A, Van de Perre P, Tuaillon E. QuantiFERON-TB Gold Plus Assay in Patients With Latent vs. Active Tuberculosis in a Low Incidence Setting: Level of IFN-γ, CD4/CD8 Responses, and Release of IL-2, IP-10, and MIG. Front Microbiol 2022;13:825021. [DOI: 10.3389/fmicb.2022.825021] [Reference Citation Analysis]
4 Xu Y, Yang Q, Zhou J, Zhou F, Hezhang Y, Gao Y, Shao L, Shi J, Ruan Q, Zhang W. Comparison of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold-Plus in the Diagnosis of Mycobacterium tuberculosis Infections in Immunocompromised Patients: a Real-World Study. Microbiol Spectr 2022;:e0187021. [PMID: 35234509 DOI: 10.1128/spectrum.01870-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Soler-Garcia A, Gamell A, Pérez-Porcuna T, Soriano-Arandes A, Santiago B, Tórtola T, Ruiz-Serrano MJ, Korta Murua JJ, Bustillo-Alonso M, Garrote-Llanos MI, Rodríguez-Molino P, Piqueras AI, Tagarro A, Monsonís M, Tebruegge M, Noguera-Julian A; QFT-Plus Study Group of the Spanish Pediatric TB Research Network. Performance of QuantiFERON-TB Gold Plus assays in children and adolescents at risk of tuberculosis: a cross-sectional multicentre study. Thorax 2021:thoraxjnl-2021-217592. [PMID: 34876500 DOI: 10.1136/thoraxjnl-2021-217592] [Reference Citation Analysis]
6 Li Z, Hu J, Liu P, Cui D, Di H, Wu S. Microarray-based selection of a serum biomarker panel that can discriminate between latent and active pulmonary TB. Sci Rep 2021;11:14516. [PMID: 34267288 DOI: 10.1038/s41598-021-93893-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Viana Machado F, Morais C, Santos S, Reis R. Evaluation of CD8+ response in QuantiFERON-TB Gold Plus as a marker of recent infection. Respir Med 2021;185:106508. [PMID: 34171790 DOI: 10.1016/j.rmed.2021.106508] [Reference Citation Analysis]
8 Hong JY, Kim A, Park SY, Cho SN, Dockrell HM, Hur YG. Screening for Mycobacterium tuberculosis Infection Using Beijing/K Strain-Specific Peptides in a School Outbreak Cohort. Front Cell Infect Microbiol 2021;11:599386. [PMID: 33869073 DOI: 10.3389/fcimb.2021.599386] [Reference Citation Analysis]